Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Shoji, Hirotaka ^a,b   Yoshio, Sachiyo ^a   Mano, Yohei ^a   Kumagai, Erina ^a   Sugiyama, Masaya ^a   Korenaga, Masaaki ^a   Arai, Taeang ^c   Itokawa, Norio ^c   Atsukawa, Masanori ^c   Aikata, Hiroshi ^d   Hyogo, Hideyuki ^d,e   Chayama, Kazuaki ^d   Ohashi, Tomohiko ^f   Ito, Kiyoaki ^f   Yoneda, Masashi ^f   Nozaki, Yuichi ^a   Kawaguchi, Takumi ^g   Torimura, Takuji ^g   Abe, Masanori ^h   Hiasa, Yoichi ^h   Fukai, Moto ^b   Kamiyama, Toshiya ^b   Taketomi, Akinobu ^b   Mizokami, Masashi ^a   Kanto, Tatsuya ^a   more..

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

^e JA Hiroshima General Hospital at Jigozen   (Japan)

^f AICHI MEDICAL UNIVERSITY   (Japan)

^g KURUME UNIVERSITY   (Japan)

^h EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN DERIVATIVE; INTERLEUKIN-34, HUMAN;

ADULT; AGED; BIOSYNTHESIS; BLOOD; CELL CULTURE; COMPLICATION; FEMALE; FIBROBLAST; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; MALE; METABOLISM; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CELLS, CULTURED; FEMALE; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKINS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; ROC CURVE;

EID: 84976871484     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep28814     Document Type: Article

References (38)

1. Wong, V. W. Nonalcoholic fatty liver disease in Asia: a story of growth. J Gastroenterol Hepatol 28, 18-23, doi: 10.1111/jgh.12011 (2013).
2. Farrell, G. C., Larter, C. Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology (Baltimore, Md.) 43, S99-S112, doi: 10.1002/hep.20973 (2006).
3. Yki-Jarvinen, H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. The lancet. Diabetes & endocrinology 2, 901-910, doi: 10.1016/s2213-8587(14)70032-4 (2014).
4. Pagano, G. et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology (Baltimore, Md.) 35, 367-372, doi: 10.1053/jhep.2002.30690 (2002).
5. Huang, R. C. et al. Importance of cardiometabolic risk factors in the association between nonalcoholic fatty liver disease and arterial stiffness in adolescents. Hepatology (Baltimore, Md.) 58, 1306-1314, doi: 10.1002/hep.26495 (2013).
6. Seko, Y. et al. Predictors of malignancies and overall mortality in Japanese patients with biopsy-proven non-alcoholic fatty liver disease. Hepatol Res 45, 728-738, doi: 10.1111/hepr.12407 (2015).
7. Bugianesi, E. et al. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 123, 134-140, doi: 10.1053/gast.2002.34168 (2002).
8. Watanabe, S. et al. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res 45, 363-377, doi: 10.1111/hepr.12511 (2015).
9. Tilg, H., Moschen, A. R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology (Baltimore, Md.) 52, 1836-1846, doi: 10.1002/hep.24001 (2010).
10. Angulo, P. Nonalcoholic fatty liver disease. N Engl J Med 346, 1221-1231, doi: 10.1056/NEJMra011775 (2002).
11. Sumida, Y., Nakajima, A., Itoh, Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 20, 475-485, doi: 10.3748/wjg.v20.i2.475 (2014).
12. Cadranel, J. F., Rufat, P., Degos, F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology (Baltimore, Md.) 32, 477-481, doi: 10.1053/jhep.2000.16602 (2000).
13. Abe, M. et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of nonalcoholic fatty liver disease. Journal of gastroenterology 50, 776-784, doi: 10.1007/s00535-014-1007-2 (2015).
14. Fujii, H. et al. Applicability of BARD score to Japanese patients with NAFLD. Gut 58, 1566-1567; author reply 1567, doi: 10.1136/gut.2009.182758 (2009).
15. Ramachandran, P., Iredale, J. P. Macrophages: central regulators of hepatic fibrogenesis and fibrosis resolution. J Hepatol 56, 1417-1419, doi: 10.1016/j.jhep.2011.10.026 (2012).
16. Bataller, R., Brenner, D. A. Liver fibrosis. Journal of Clinical Investigation 115, 209-218, doi: 10.1172/jci24282 (2005).
17. Itoh, M. et al. Hepatic crown-like structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humans. PLoS One 8, e82163, doi: 10.1371/journal.pone.0082163 (2013).
18. Lin, H. et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 320, 807-811, doi: 10.1126/science.1154370 (2008).
19. Foucher, E. D. et al. IL-34 induces the differentiation of human monocytes into immunosuppressive macrophages. antagonistic effects of GM-CSF and IFNgamma. PLoS One 8, e56045, doi: 10.1371/journal.pone.0056045 (2013).
20. Preisser, L. et al. IL-34 and macrophage colony-stimulating factor are overexpressed in hepatitis C virus fibrosis and induce profibrotic macrophages that promote collagen synthesis by hepatic stellate cells. Hepatology (Baltimore, Md.) 60, 1879-1890, doi: 10.1002/hep.27328 (2014).
21. Kazankov, K. et al. Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology (Baltimore, Md.) 60, 521-530, doi: 10.1002/hep.27129 (2014).
22. Moller, H. J. Soluble CD163. Scand J Clin Lab Invest 72, 1-13, doi: 10.3109/00365513.2011.626868 (2012).
23. Weaver, L. K. et al. Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol 80, 26-35, doi: 10.1189/jlb.1205756 (2006).
24. Bertola, A. et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS One 5, e13577, doi: 10.1371/journal.pone.0013577 (2010).
25. Crespo, J. et al. Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology (Baltimore, Md.) 34, 1158-1163, doi: 10.1053/jhep.2001.29628 (2001).
26. Siddique, A., Kowdley, K. V. Insulin resistance and other metabolic risk factors in the pathogenesis of hepatocellular carcinoma. Clin Liver Dis 15, 281-296, vii-x, doi: 10.1016/j.cld.2011.03.007 (2011).
27. Yu, J., Shen, J., Sun, T. T., Zhang, X., Wong, N. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol 23, 483-491, doi: 10.1016/j.semcancer.2013.07.003 (2013).
28. Tosello-Trampont, A. C., Landes, S. G., Nguyen, V., Novobrantseva, T. I., Hahn, Y. S. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. J Biol Chem 287, 40161-40172, doi: 10.1074/jbc.M112.417014 (2012).
29. Chang, E. J. et al. IL-34 is associated with obesity, chronic inflammation, and insulin resistance. J Clin Endocrinol Metab 99, E1263-E1271, doi: 10.1210/jc.2013-4409 (2014).
30. Affo, S. et al. CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis. Gut 63, 1782-1792, doi: 10.1136/gutjnl-2013-306098 (2014).
31. Baek, J. H. et al. IL-34 mediates acute kidney injury and worsens subsequent chronic kidney disease. The Journal of clinical investigation 125, 3198-3214, doi:10.1172/JCI81166 (2015).
32. Zhou, S. L. et al. miR-28-5p-IL-34-Macrophage Feedback Loop Modulates Hepatocellular Carcinoma Metastasis. Hepatology (Baltimore, Md.), doi: 10.1002/hep.28445 (2016).
33. Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., Bacon, B. R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94, 2467-2474, doi: 10.1111/j.1572-0241.1999.01377.x (1999).
34. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology (Baltimore, Md.) 20, 15-20 (1994).
35. Wai, C. T. et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (Baltimore, Md.) 38, 518-526, doi: 10.1053/jhep.2003.50346 (2003).
36. Vallet-Pichard, A. et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology (Baltimore, Md.) 46, 32-36, doi: 10.1002/hep.21669 (2007).
37. Angulo, P. et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (Baltimore, Md.) 45, 846-854, doi: 10.1002/hep.21496 (2007).
38. Matsubara, T. et al. TIE2-expressing monocytes as a diagnostic marker for hepatocellular carcinoma correlates with angiogenesis. Hepatology (Baltimore, Md.) 57, 1416-1425, doi: 10.1002/hep.25965 (2013).